The Psychedelic Renaissance Is Now Mainstream Medicine

MDMA-assisted therapy is under FDA review, psilocybin is legal for therapy in several states, and ketamine clinics are opening everywhere. Here is the honest state of the science.

The psychedelic renaissance in psychiatry — the return of research attention to drugs including psilocybin, MDMA, ketamine, and LSD as potential therapeutic agents after a 50-year research hiatus following the 1970 Controlled Substances Act — has in 2026 reached a point where several of these agents have either received regulatory approval or are in the final stages of approval processes that have shifted from theoretical possibility to practical imminent reality.

Ketamine and its derivative esketamine (Spravato) have the most established regulatory and clinical position: FDA approved since 2019 for treatment-resistant depression, available through licensed ketamine infusion clinics, and demonstrating rapid (often within hours) antidepressant effects in patients who have not responded to multiple conventional antidepressants. The mechanism — NMDA receptor antagonism producing glutamate release and synaptogenesis — is different from all existing antidepressants and explains both its rapid onset and its effectiveness in treatment-resistant patients whose serotonergic and noradrenergic systems have not responded to conventional treatment.

Psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression has received FDA Breakthrough Therapy Designation and has been legalised for therapeutic use in Oregon (2023), Colorado (2023), and several other US states. The Phase 3 trials results — which were expected to support FDA approval in 2024-2025 — have been delayed by FDA questions about trial design, and approval timing is now uncertain. Australian regulators approved psilocybin-assisted therapy in 2023, giving Australian therapists legal access ahead of US counterparts.

MDMA-assisted therapy for PTSD — which showed 67 percent PTSD response rates in Phase 3 trials compared to 32 percent for placebo plus therapy — received an FDA advisory committee rejection in 2024 citing methodological concerns about trial blinding. The revised application and additional data submission are under review. The specific PTSD population who might benefit — military veterans, sexual assault survivors, first responders — has made this the most politically charged of the psychedelic therapy regulatory questions.